1. Kerc J, inventor. Stable Pharmaceutical formulation comprising a HMG CoA reductase inhibitor. US Patent Application, 22 Oct 2009.
2. Kerc J, Salobir M, Bavec S, inventors. Atorvastatin calcium in a pharmaceutical form composition thereof and pharmaceutical formulation comprising atorvastatin calcium. US Patent 7030151, 18 April 2006.
3. Kearny AS, Crawford LF, Mehta SC, Radebaugh GW. The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. Pharm Res. 1993;10:1461–5.
4. Ishigami M, Honda T, Takashi W. A comparison of the effects of 3-hydroxy-3- methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos. 2001;29:282–8.
5. Mills N, Muhammad NA, Weiss J, Nesbitt RU, inventors. Stable oral CI-981 formulation and process for preparing same.US Patent 6126971, 3 Oct 2000.